Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.38 |
| ▸ | GSR | P00390 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741845 | 1.00 | GRM2 (0.43) | GRM2ALDH1A1GRM6CYP1A2ALOX15 | |
| SCHEMBL22680029 | 0.90 | GSR (0.42) | GRM2ALDH1A1CYP1A2CYP2C19GSR | |
| SCHEMBL4407721 | 0.82 | SLC7A5 (0.41) | ALDH1A1CYP1A2ALOX15KMT2AMEN1 | |
| SCHEMBL5292027 | 0.82 | SLC7A5 (0.41) | ALDH1A1CYP1A2ALOX15KMT2AMEN1 | |
| SCHEMBL7354483 | 0.82 | SLC7A5 (0.41) | ALDH1A1CYP1A2ALOX15KMT2AMEN1 | |
| SCHEMBL8619805 | 0.81 | LTA4H (0.32) | — | |
| SCHEMBL21110516 | 0.80 | GSR (0.37) | KMT2AGSR | |
| SCHEMBL15160577 | 0.79 | GABRR1 (0.38) | CYP1A2BLM | |
| SCHEMBL20757241 | 0.76 | TDP1 (0.45) | GSR | |
| SCHEMBL12809020 | 0.76 | TDP1 (0.45) | GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4314017-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023069332-A1 | CELL PERMEABLE MACROCYCLIC PEPTIDES USEFUL FOR EIF4E CAP-BINDING SITE INHIBITION | MERCK SHARP & DOHME LLC (US) | 2023-04-27 | — | — | WO | claimed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | claimed |
| EP-0655463-A1 | Cyclic hexapeptides having endothelin antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | claimed |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-12-11 | — | — | US | disclosed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GRM2 4522/4885ALDH1A1 3808/4885GRM6 3301/4885 |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | MAN2B1, GBA1, SSTR1 | GRM2 1615/4885ALDH1A1 625/4885GRM6 2927/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GRM2 4013/4885ALDH1A1 4194/4885GRM6 2920/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | GRM2 4284/4885ALDH1A1 3502/4885GRM6 3859/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GRM2 4391/4885ALDH1A1 3851/4885GRM6 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.